Technical Data
Activin A Receptor Type IA (ACVR1, Activin Receptor-like Kinase 2, Activin Receptor Type 1A Precursor, ACTR-IA, ACVRLK2, ALK2, ALK-2)
Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I and two type II receptors. Unlike ACVR1B and ACVR1C, ACVR1, also known as activin receptor-like kinase 2 (ALK2), can not transduce activin-mediated signaling, but will transduce BMP and Mullerian inhibiting substance (MIS) group signaling. It is thought that ACVR1 also inhibits activin signaling by blocking the binding of activin to its type II receptor. Recent studies indicate that genetic variation in ACVR1 is associated with polycystic ovary syndrome, suggesting that ACVR1 signaling contributes to disturbed folliculogenesis in these patients. At least four isoforms of ACVR1 are known to exist. This antibody is predicted to have no cross-reactivity to ACVR1B or ACVR1C.

Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1-2ug/ml
Optimal dilutions to be determined by the researcher.

Positive Control:
A549 Cell Lysate

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
100ug-20CBlue IceHumanRabbit
Synthetic peptide corresponding to 14aa from near the amino terminus of the human ACVR1.
Purified by immunoaffinity chromatography.
Supplied as a liquid in PBS, 0.02% sodium azide.
Recognizes human Activin A receptor type IA. Species Crossreactivity: mouse
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Tsuchida K, Sawchenko PN, Nishikawa S, et al. Mol. Cell. Neurosci. 1996; 76:467-78. 2. ten Dijke P, Yamashita H, Sampath TK, et al. J. Biol. Chem. 1994; 269:16985-8. 3. Clarke TR, Hoshiya Y, Yi SE, et al. Mol. Endocrinol. 2001; 15:946-59. 4. Renlund N, ONeill FH, Zhang L, et al. J. Endocrinol. 2007; 195:95-103.